By Alfred Akuki
Multinational pharmaceutical company,
GlaxoSmithKline (GSK) has announced the recall of over 590,000 Salbutamol
(Ventolin) inhalers from the US market, saying there could be issues with the
delivery technique.
The recall is for three lots of Ventolin HFA 200D
inhalers with lot numbers 6ZP0003, 6ZP9944 and 6ZP9848.
The inhalers, according to reports, have been
distributed to hospitals, pharmacies, retailers and wholesalers in the United
States.
“There is attainable risk that the affected
inhalers could potentially not deliver the stated number of actuations,”
according to GSK spokesman Juan Carlos Molina. “We continue to investigate the
situation in order to identify the root lead to and implement appropriate
corrective and preventative actions.”
The recall is not directed at individuals, but
those with inhalers from the recalled lots have been advised to contact the company.
